Swiss peptide and oligonucleotide manufacturer Bachem has announced major investments across its global site network to expand production capabilities in response to surging demand for peptide and oligonucleotide therapeutics. The company is directing funding to improve facilities at its Bubendorf, Vista, and St Helens sites while developing a new manufacturing location in Sisseln.
The expansion initiative comes as the global market for obesity drugs is expected to increase by more than 15-fold by 2030, driving unprecedented demand for peptide-based therapeutics. Bachem continues to scale operations in alignment with this rising market demand.
Bubendorf Site Adds State-of-the-Art Building K Facility
At its Bubendorf location, Bachem is expanding large-scale operations with a new state-of-the-art production facility designated as Building K. The facility incorporates high-capacity production cells designed for scalable synthesis, along with advanced energy systems including heating, cooling, water, and cold storage infrastructure. A specialized tank farm has been integrated to support large-scale manufacturing operations.
Vista Site Achieves Nearly One Metric Ton Annual Capacity
Bachem has directed significant funding to its Vista site to increase annual peptide production capacity to nearly one metric ton. The enhanced facility will feature large-scale solid-phase peptide synthesis (SPPS) reactors for efficient peptide synthesis and a cleavage equipment train equipped with two filter dryers to enhance throughput.
Additional improvements include an increased tank farm and waste management systems to support high-volume operations, along with an automated glass washer and new heating and chilling systems designed to improve operational efficiency.
UK and Swiss Sites Expand Capabilities
Infrastructure improvements at Bachem's St Helens site have resulted in a doubling of output capacity, with operations focused on the development of research chemicals. The enhanced capabilities position the UK facility to better serve the growing demand for diagnostic peptides and research applications.
Separately, Bachem is developing a new manufacturing site in Sisseln, located in northwestern Switzerland. Concept designs for the facility are currently underway, representing the company's continued commitment to expanding its European manufacturing footprint.
